ArticleBritish journal of cancer2023

Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis.

Maren Juliane Egidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.